MMP9 and COVID-19: Finally, among the 15 COVID-19 patients with severe NS on hospital admission requiring PL for diagnostic purposes, an investigation of neuronal and astrocyte damage (NfL and GFAP), myeloid activation (sCD163) and BBB alteration biomarkers (MMP-9 and TIMP-1) on CSF samples was performed (Table 4).